SCHEMBL16290457

SCHEMBL16290457

CC(C)(C)OC(=O)NS(=O)(=O)NC1CCc2cc(C#N)cc(Cl)c21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPAS1 Q99814 1/20 0.37
▸ DRD2 P14416 1/20 0.36
▸ CA12 O43570 4/20 0.33
▸ CA14 Q9ULX7 3/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA7 P43166 1/20 0.33
▸ ENPP1 P22413 1/20 0.33
▸ JAK3 P52333 1/20 0.32
▸ BTK Q06187 1/20 0.32
▸ EGLN2 Q96KS0 1/20 0.32
▸ RORC P51449 2/20 0.32
▸ CA2 P00918 2/20 0.32
▸ NR3C1 P04150 1/20 0.32
▸ BRS3 P32247 1/20 0.32
▸ STS P08842 3/20 0.32
▸ CA9 Q16790 1/20 0.31
▸ PDK1 Q15118 1/20 0.31
▸ PDK2 Q15119 1/20 0.31
▸ PDK3 Q15120 1/20 0.31
▸ PDK4 Q16654 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16290323 0.85 CA12 (0.35) EPAS1CA12CA14CA1CA7
SCHEMBL16290391 0.80 STS (0.42) DRD2CA12CA14CA1CA7
SCHEMBL18710451 0.79 DRD2 (0.36) EPAS1DRD2EGLN2PDK1PDK2
SCHEMBL16290506 0.78 BDKRB1 (0.45) CA12CA14CA1CA7RORC
SCHEMBL16307307 0.76 CA1 (0.43) DRD2CA1CA2
SCHEMBL16290342 0.76 CA1 (0.43) DRD2CA1CA2
SCHEMBL16307306 0.76 CA1 (0.43) DRD2CA1CA2
SCHEMBL16290658 0.75 CA12 (0.36) EPAS1CA12CA14CA1CA7
SCHEMBL21178718 0.72 DRD2 (0.43) EPAS1DRD2SIRT2SIRT1
SCHEMBL16290446 0.69 CA12 (0.40) EPAS1CA12CA14CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865663-B1 NOVEL INDANESULFAMIDE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 — — EP disclosed
EP-2865663-B1 NOVEL INDANESULFAMIDE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 — — EP disclosed
EP-2865663-A1 NOVEL INDANESULFAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2015-04-29 — — EP disclosed
EP-2865663-A1 NOVEL INDANESULFAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2015-04-29 — — EP disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 — — US disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 — — US disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 — — US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 — — US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 — — US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES SCN1A, SCN7A, SCN2A EPAS1 3227/4885DRD2 793/4885CA12 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback